King's College London

Research portal

Polyethylene Glycol Conjugated Polymeric Nanocapsules for Targeted Delivery of Quercetin to Folate-Expressing Cancer Cells In Vitro and In Vivo

Research output: Contribution to journalArticle

Riham El-Gogary, Noelia Rubio, Julie Tzu-Wen Wang, Wafa' Al-Jamal Al-Jamal, Maxime Bourgognon, Houmam Kafa, Muniba Naeem, Rebecca Klippstein, Vincenzo Abbate, Frederic Leroux, Sara Bals, Gustav Van Tendeloo, Armany O. Kamal, Gehanna A.S. Awad, Naheed D. Mortada, Khuloud Al-Jamal

Original languageEnglish
Pages (from-to)1384-1401
Number of pages18
JournalACS Nano
Volume8
Issue number2
Early online date23 Jan 2014
DOIs
Publication statusPublished - 25 Feb 2014

King's Authors

Abstract

In this work we describe the formulation and characterization of chemically modified polymeric nanocapsules incorporating the anticancer drug, quercetin, for the passive and active targeting to tumors. Folic acid was conjugated to poly(lactide-co-glycolide) (PLGA) polymer to facilitate active targeting to cancer cells. Two different methods for the conjugation of PLGA to folic acid were employed utilizing polyethylene glycol (PEG) as a spacer. Characterization of the conjugates was performed using FTIR and 1H NMR studies. The PEG and folic acid content was independent of the conjugation methodology employed. PEGylation has shown to reduce the size of the nanocapsule; moreover, zeta-potential was shown to be polymer-type dependent. Comparative studies on the cytotoxicity and cellular uptake of the different formulations by HeLa cells, in the presence and absence of excess folic acid, were carried out using MTT assay and Confocal Laser Scanning Microscopy, respectively. Both results confirmed the selective uptake and cytotoxicity of the folic acid targeted nanocapsules to the folate enriched cancer cells in a folate-dependent manner. Finally, the passive tumor accumulation and the active targeting of the nanocapsules to folate-expressing cells were confirmed upon intravenous administration in HeLa or IGROV-1 tumor-bearing mice. The developed nanocapsules provide a system for targeted delivery of a range of hydrophobic anticancer drugs in vivo.

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454